Skip to main content
Explore URMC

REALIZE: CVL-865 to Treat Epilepsy

Research Question:
What is the efficacy of CVL-865 as adjunctive therapy compared with placebo in subjects with focal onset seizures?

Basic Study Information

This placebo-controlled, double-blind trial is designed to assess the efficacy, safety and tolerability profile of CVL-865 as adjunctive treatment in subjects with drug-resistant focal onset seizures. Subjects will be randomized into one of three arms in a 1:1:1 ratio: one of two formulations of the study drug and placebo. For more information, go to

Location: University of Rochester Medical Center
Study Reference #: 4612

Lead Researcher (Principal Investigator)

Lead Researcher:  Trenton Tollefson

Study Contact Information

Study Coordinator: Cate Concannon
Phone: (585) 275-0404

Additional Study Details

Study Details:
Eligibility: Ages 18 - 75 (inclusive) with a diagnosis of focal epilepsy.

Number of Visits:  6 to 10
Transportation Coverage:  Yes
Reimbursement:  Yes

Learn More About These Conditions

More information about Epilepsy

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search